Immunovaccine (TSX-V) is advancing its patented DepoVax™ delivery technology and will be taking a therapeutic cancer vaccine into Phase 1 clinical trials in Q1 2010. The company is also negotiating partnership and licensing opportunities.
Immunovaccine is formulating FIT Biotech’s DNA vaccines with DepoVax™ to advance a therapeutic HIV vaccine.